1. Home
  2. MRVI vs JCE Comparison

MRVI vs JCE Comparison

Compare MRVI & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • JCE
  • Stock Information
  • Founded
  • MRVI 2014
  • JCE 2007
  • Country
  • MRVI United States
  • JCE United States
  • Employees
  • MRVI N/A
  • JCE N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • JCE Trusts Except Educational Religious and Charitable
  • Sector
  • MRVI Health Care
  • JCE Finance
  • Exchange
  • MRVI Nasdaq
  • JCE Nasdaq
  • Market Cap
  • MRVI 312.4M
  • JCE 253.3M
  • IPO Year
  • MRVI 2020
  • JCE N/A
  • Fundamental
  • Price
  • MRVI $2.67
  • JCE $15.42
  • Analyst Decision
  • MRVI Hold
  • JCE
  • Analyst Count
  • MRVI 10
  • JCE 0
  • Target Price
  • MRVI $6.84
  • JCE N/A
  • AVG Volume (30 Days)
  • MRVI 1.9M
  • JCE 49.7K
  • Earning Date
  • MRVI 08-06-2025
  • JCE 01-01-0001
  • Dividend Yield
  • MRVI N/A
  • JCE 9.26%
  • EPS Growth
  • MRVI N/A
  • JCE N/A
  • EPS
  • MRVI N/A
  • JCE N/A
  • Revenue
  • MRVI $241,856,000.00
  • JCE N/A
  • Revenue This Year
  • MRVI N/A
  • JCE N/A
  • Revenue Next Year
  • MRVI $10.62
  • JCE N/A
  • P/E Ratio
  • MRVI N/A
  • JCE N/A
  • Revenue Growth
  • MRVI N/A
  • JCE N/A
  • 52 Week Low
  • MRVI $1.67
  • JCE $11.64
  • 52 Week High
  • MRVI $10.03
  • JCE $14.28
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 59.30
  • JCE 58.98
  • Support Level
  • MRVI $2.52
  • JCE $15.31
  • Resistance Level
  • MRVI $2.93
  • JCE $15.54
  • Average True Range (ATR)
  • MRVI 0.18
  • JCE 0.22
  • MACD
  • MRVI 0.03
  • JCE 0.02
  • Stochastic Oscillator
  • MRVI 69.41
  • JCE 88.24

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

Share on Social Networks: